The period for CME/CE credit for this activity has expired.


Incretin Insider: Incretin Mimetics 2008 in Review


After completing the demographic questionnaire and the CME posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.

CME/CE Information

Term of Approval

Release date: January 2009
Expiration date: January 31, 2010

Program Overview

Despite the proven benefits of glycemic control in type 2 diabetes, recent studies demonstrate that a staggering 45% of patients with type 2 diabetes are not reaching an A1C goal of < 7%. Among the numerous reasons for therapeutic failure are progressive β-cell decline and the adverse effects of conventional therapies. Agents that provide some of the numerous beneficial properties of the incretin hormone, glucagon-like peptide-1 (GLP-1), offer the potential to address many of the unmet therapeutic needs of conventional type 2 diabetes treatments. Incretin mimetics (also known as GLP-1 receptor agonists) have been shown to provide glycemic control with a low risk of hypoglycemia, to promote weight loss rather than weight gain, and to offer the potential to modify underlying disease pathophysiology. A wealth of new data on incretin mimetics were released and published in 2008. This publication will summarize these key findings and offer insight into the clinical utility of incretin mimetics.

Intended Audience

This activity is intended for endocrinologists as well as other physicians and healthcare professionals treating patients with type 2 diabetes.

Learning Objectives

After participating in this activity, the participant should be able to:
  • Describe defects in incretin secretion and incretin action that occur in type 2 diabetes
  • Explain at least 3 of the glucoregulatory effects of GLP-1
  • Summarize the data recently presented and published on incretin mimetics
  • Discuss the implications of recently published data on the use of incretin mimetics in clinical practice

Accreditation and Credit Designation Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for Medical and Nursing Education (IMNE) and International Medical Press (IMP). IMNE is accredited by the ACCME to provide continuing medical education for physicians. IMNE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


In compliance with the ACCME’s Policy on Commercial Support, it is the policy of IMNE and IMP to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label product or investigational use of pharmaceutical and medical device products. In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict have been made in the form of external peer review of educational content. The following disclosures have been made:


Vivian Fonseca, MD, FACE, MRCP
Research support: GlaxoSmithKline; Novartis; Novo Nordisk; Takeda Pharmaceuticals North America, Inc; AstraZeneca; Pfizer Inc; sanofi-aventis; Eli Lilly and Company; Daiichi Sankyo, Inc; National Institutes of Health; American Diabetes Association
Consultant/Speaker: GlaxoSmithKline; Novartis; Takeda Pharmaceuticals North America; Pfizer Inc; sanofi-aventis; Eli Lilly and Company; Daiichi Sankyo, Inc; Novo Nordisk

Dr Fonseca has disclosed that he will reference unlabeled/unapproved uses of incretin-based therapies in this publication.

Derek LeRoith, MD, PhD, FACP
Speakers Bureau: Merck & Co, Inc; Takeda Pharmaceuticals North America; sanofi-aventis
Consultant: Bristol-Myers Squibb Company; AstraZeneca; sanofi-aventis
Stockholder: Roche Pharmaceuticals

Dr LeRoith has disclosed that he will reference unlabeled/unapproved uses of incretin-based therapies in this publication.

Lawrence Blonde, MD, FACP, FACE
Research Support: Amylin Pharmaceuticals, Inc; AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; MannKind Corporation; Merck & Co, Inc; Novo Nordisk Inc; Novartis; Pfizer Inc; sanofi-aventis
Speakers Bureau/Consultant: Abbott; Amylin Pharmaceuticals, Inc; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc; Eli Lilly and Company; GlaxoSmithKline; LifeScan, Inc; Merck & Co, Inc; Novartis; Novo Nordisk Inc; Pfizer Inc; sanofi-aventis
Consultant: Halozyme Therapeutics
Spousal Commercial Interests: Stockholder: Amylin Pharmaceuticals, Inc; Pfizer Inc

Dr Blonde has disclosed that he will reference unlabeled/unapproved uses of incretin-based therapies in this publication.


Steve Weinman, RN
Executive Director
Disclosures: Nothing to disclose
Amy Groves
Director, Program Development
Disclosures: Nothing to disclose
Katie Fidanza
Program Development Executive
Disclosures: Nothing to disclose
Kim McFarland, PhD
Senior Medical Writer
Disclosures: GlaxoSmithKline: Spouse employee, spouse stocks; Pfizer Inc: stocks; Procter & Gamble: stocks
Robert Hash, MD
External Peer and Conflict of Interest Reviewer
Vice Dean of Academic Affairs
Texas A&M College of Medicine
Houston, Texas
Disclosures: Nothing to disclose
Martin Quan, MD
External Peer and Conflict of Interest Reviewer
Professor of Clinical Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Disclosures: Nothing to disclose


This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Novo Nordisk Inc.

Method of Obtaining CME Credit

CME credit/verification is offered upon successful completion of the post-test with a minimum passing score of 70%. A printable certificate will be made available upon successful post-test completion.
Questions or comments can be addressed to
Please allow 6-12 weeks for issuance of CME credit.

 I have read and understand the CME Information indexed above.

    • Incretin Insider: Incretin Mimetics 2008 in Review GraphicClick here to view the activity (.pdf)
    • Demographic Questionnaire - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    • CME Posttest and Evaluation - This should be completed after the demographic questionnaire.

    You can click on each section to preview this activity but you must be signed in to participate and receive CME credit. New to Click here to register.